Risk factors for checkpoint inhibitor pneumonitis in lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

BackgroundImmune checkpoint inhibitors (ICIs) significantly improve survival in lung cancer patients. However, checkpoint inhibitor pneumonitis (CIP) remains a critical safety concern. This meta-analysis systematically evaluates demographic, clinical, and laboratory risk factors associated with CIP...

Full description

Bibliographic Details
Published in:Frontiers in Immunology
Main Authors: Xiaoqing Zhou, Yingnan Xu, Yuanyuan Ying, Ruilin Chen, Zhen Wang, Xin Lv
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Subjects:
meta-analysis
checkpoint inhibitor pneumonitis
immune checkpoint inhibitors
risk factor
immune-related adverse events
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1607170/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1607170/full

Similar Items